2026-05-24

HY spreads at distress levels - 700bps, recession-associated

Fed net liquidity surged $207bn in 4 weeks - significant injection, risk-on tailwind

Platinum volume spike - 258.6× the 20-day average (13,124 vs 50 avg)

Silver volume spike - 13.9× the 20-day average (25,615 vs 1,841 avg)

Gold volume spike - 257.2× the 20-day average (106,230 vs 413 avg)

Copper volume spike - 18.0× the 20-day average (41,401 vs 2,303 avg)

OSINT: Uncertainty Surrounds Prospective Peace Deal

Saudi Arabia (Dhahran): drought conditions detected - potential oil supply impact

Cocoa volume spike - 2.5× the 20-day average (14,971 vs 6,107 avg)

Coffee volume spike - 2.8× the 20-day average (8,179 vs 2,897 avg)

OSINT: Exit Taxes Ineffective as States Face Fiscal Collapse

FDA approves TEFLARO (AbbVie) - new revenue stream

FDA approves TEFLARO (AbbVie) - new revenue stream

FDA approves ACULAR LS (AbbVie) - new revenue stream

FDA approves TEFLARO (AbbVie) - new revenue stream

FDA approves ACULAR LS (AbbVie) - new revenue stream

FDA approves NORVIR (AbbVie) - new revenue stream

FDA approves KALETRA (AbbVie) - new revenue stream

FDA approves drug (AbbVie) - new revenue stream

FDA approves drug (AbbVie) - new revenue stream

FDA approves drug (AbbVie) - new revenue stream

FDA approves drug (AbbVie) - new revenue stream

FDA approves KALETRA (AbbVie) - new revenue stream

FDA approves NORVIR (AbbVie) - new revenue stream

FDA approves drug (AbbVie) - new revenue stream

FDA approves DALVANCE (AbbVie) - new revenue stream

FDA approves drug (AbbVie) - new revenue stream

FDA approves ACULAR LS (AbbVie) - new revenue stream

FDA approves KALETRA (AbbVie) - new revenue stream

FDA approves DALVANCE (AbbVie) - new revenue stream

FDA approves DALVANCE (AbbVie) - new revenue stream

FDA approves NORVIR (AbbVie) - new revenue stream

FDA approves ZITHROMAX (PFIZER) - new revenue stream

FDA approves DEPO-MEDROL (PFIZER) - new revenue stream

FDA approves LOMOTIL (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves LOMOTIL (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves ZITHROMAX (PFIZER) - new revenue stream

FDA approves PREPIDIL (PFIZER) - new revenue stream

FDA approves PREPIDIL (PFIZER) - new revenue stream

FDA approves LOMOTIL (PFIZER) - new revenue stream

FDA approves DEPO-MEDROL (PFIZER) - new revenue stream

FDA approves ZITHROMAX (PFIZER) - new revenue stream

FDA approves ZITHROMAX (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves LORBRENA (PFIZER) - new revenue stream

FDA approves PREPIDIL (PFIZER) - new revenue stream

FDA approves ZITHROMAX (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves LORBRENA (PFIZER) - new revenue stream

FDA approves ZITHROMAX (PFIZER) - new revenue stream

FDA approves DEPO-MEDROL (PFIZER) - new revenue stream

FDA approves LORBRENA (PFIZER) - new revenue stream

Beat consensus by 52.7% - EPS $-0.3 vs $-0.6341 estimate

Q3-2025: Beat consensus by 5.7% - EPS $1.02 vs $0.9647 estimate

Beat consensus by 5.8% - EPS $1.92 vs $1.814 estimate

Q3-2025: Beat consensus by 6.5% - EPS $1.61 vs $1.5122 estimate

Q4-2025: Beat consensus by 23.9% - EPS $2.68 vs $2.1639 estimate

Q3-2025: Missed consensus by 8.9% - EPS $1.93 vs $2.1176 estimate

Missed consensus by 9.9% - EPS $1.91 vs $2.121 estimate

Q4-2025: Beat consensus by 5.2% - EPS $0.44 vs $0.4182 estimate

Q3-2025: Beat consensus by 6.5% - EPS $0.43 vs $0.4039 estimate

Q1-2026: Beat consensus by 18.9% - EPS $0.49 vs $0.4121 estimate

Q4-2025: Beat consensus by 9.4% - EPS $1884 vs $1722.3174 estimate

Q2-2025: Missed consensus by 80.7% - EPS $-0.18 vs $-0.0996 estimate

Q4-2025: Missed consensus by 185.6% - EPS $-0.5 vs $-0.1751 estimate

Q1-2026: Missed consensus by 165.6% - EPS $-0.26 vs $-0.0979 estimate

Q3-2025: Beat consensus by 200.9% - EPS $0.13 vs $-0.1288 estimate

Missed consensus by 10.0% - EPS $-1.11 vs $-1.009 estimate

Missed consensus by 9.3% - EPS $-0.88 vs $-0.805 estimate

Q3-2025: Beat consensus by 339.3% - EPS $1.33 vs $-0.5557 estimate

Q2-2025: Beat consensus by 7.8% - EPS $3.63 vs $3.3671 estimate

Q3-2025: Beat consensus by 6.5% - EPS $3.4 vs $3.1935 estimate

Q2-2022: Missed consensus by 75.3% - EPS $-0.93 vs $-0.5304 estimate

Missed consensus by 1213.7% - EPS $-3.35 vs $-0.255 estimate

Beat consensus by 31.4% - EPS $-0.56 vs $-0.816 estimate

Q4-2025: Missed consensus by 17.3% - EPS $0.76 vs $0.9191 estimate

Missed consensus by 7.6% - EPS $0.84 vs $0.909 estimate

Missed consensus by 40.6% - EPS $0.12 vs $0.202 estimate

Q2-2025: Beat consensus by 52.3% - EPS $0.2 vs $0.1313 estimate

Q1-2026: Missed consensus by 7.9% - EPS $0.4 vs $0.4343 estimate

Q1-2025: Missed consensus by 15.6% - EPS $2.66 vs $3.1522 estimate

Q4-2024: Beat consensus by 1750.5% - EPS $1.51 vs $0.0816 estimate

Q4-2025: Missed consensus by 181.1% - EPS $-0.091 vs $0.1122 estimate

Q4-2025: Missed consensus by 27.3% - EPS $0.42 vs $0.5779 estimate

Q2-2025: Beat consensus by 34.5% - EPS $2.42 vs $1.7998 estimate

Q4-2025: Beat consensus by 25.7% - EPS $5.13 vs $4.0821 estimate

Q3-2025: Beat consensus by 5.9% - EPS $3.48 vs $3.2854 estimate

Q1-2026: Beat consensus by 46.6% - EPS $7.53 vs $5.1348 estimate

Q4-2025: Beat consensus by 93.1% - EPS $0.31 vs $0.1605 estimate

Q3-2025: Missed consensus by 19.0% - EPS $0.06 vs $0.0741 estimate

Beat consensus by 7.3% - EPS $0.5 vs $0.466 estimate

Q4-2026: Beat consensus by 5.5% - EPS $0.52 vs $0.4929 estimate

Q1-2026: Missed consensus by 6.8% - EPS $0.41 vs $0.4401 estimate

Q4-2025: Beat consensus by 54.8% - EPS $0.43 vs $0.2778 estimate

Q3-2025: Missed consensus by 30.9% - EPS $0.06 vs $0.0868 estimate

Q1-2026: Beat consensus by 54.8% - EPS $0.27 vs $0.1744 estimate

Q3-2025: Beat consensus by 9.0% - EPS $-1.17 vs $-1.2863 estimate

Q2-2025: Beat consensus by 11.2% - EPS $-1.29 vs $-1.4533 estimate

Q4-2025: Missed consensus by 16.4% - EPS $-1.37 vs $-1.1766 estimate

Q4-2025: Beat consensus by 5.8% - EPS $2.21 vs $2.0887 estimate

Q1-2026: Beat consensus by 11.0% - EPS $2.43 vs $2.1897 estimate

Q4-2024: Missed consensus by 5.4% - EPS $1.15 vs $1.2154 estimate

Q2-2024: Missed consensus by 20.2% - EPS $0.46 vs $0.5768 estimate

Q1-2026: Beat consensus by 5.8% - EPS $2.99 vs $2.8261 estimate

Q4-2025: Beat consensus by 18.2% - EPS $2.29 vs $1.9371 estimate

Q3-2025: Beat consensus by 21.1% - EPS $2.92 vs $2.4111 estimate

Q4-2025: Beat consensus by 7.5% - EPS $-1.29 vs $-1.3948 estimate

Q3-2025: Missed consensus by 7.8% - EPS $-1.38 vs $-1.2807 estimate

Q2-2025: Missed consensus by 9.8% - EPS $-1.23 vs $-1.1204 estimate

Q3-2025: Beat consensus by 182.6% - EPS $0.12 vs $-0.1453 estimate

Q1-2026: Missed consensus by 44.5% - EPS $0.18 vs $0.3246 estimate

Q4-2025: Beat consensus by 53.7% - EPS $-0.124 vs $-0.2678 estimate

Beat consensus by 74.9% - EPS $-28980 vs $-115346.7 estimate

Q3-2024: Missed consensus by 152.1% - EPS $-0.18 vs $-0.0714 estimate

Q3-2024: Missed consensus by 1944.8% - EPS $-1.46 vs $-0.0714 estimate

Missed consensus by 31.1% - EPS $-36225 vs $-27631.8 estimate

Q2-2025: Missed consensus by 33.2% - EPS $0.07 vs $0.1048 estimate

Q1-2026: Missed consensus by 17.4% - EPS $0.09 vs $0.1089 estimate

Q3-2025: Beat consensus by 25.8% - EPS $0.14 vs $0.1113 estimate

Q4-2025: Missed consensus by 21.1% - EPS $0.09 vs $0.1141 estimate

Beat consensus by 76.3% - EPS $-28.8 vs $-121.584 estimate

Q3-2025: Missed consensus by 283.2% - EPS $-3.44 vs $-0.8976 estimate

Missed consensus by 1396.7% - EPS $-11.45 vs $-0.765 estimate

Beat consensus by 5.2% - EPS $2.86 vs $2.7176 estimate

SPY RSI 71.8 - overbought (crossed above 70)

BROWN FORMAN CORP search volume spiked +100 pts - unusual interest

ALEXANDRIA REAL ESTATE EQUITIES, INC. search volume spiked +100 pts - unusual interest

Q1-2026: Beat consensus by 25.2% - EPS $1.155847 vs $0.9229 estimate

Q1-2026: Missed consensus by 366.9% - EPS $-1 vs $-0.2142 estimate

Missed consensus by 59.6% - EPS $-2.36 vs $-1.479 estimate

Q3-2025: Missed consensus by 86.9% - EPS $-0.61 vs $-0.3264 estimate

Q4-2025: Missed consensus by 416.1% - EPS $-1.79 vs $-0.3468 estimate

Q3-2025: Beat consensus by 59.7% - EPS $0.2 vs $0.1252 estimate

Q1-2026: Missed consensus by 55.7% - EPS $-0.43 vs $-0.2761 estimate

Missed consensus by 199.0% - EPS $-0.1 vs $0.101 estimate

Q2-2025: Missed consensus by 892.1% - EPS $-0.64 vs $0.0808 estimate

Q2-2023: Beat consensus by 52.1% - EPS $-5.445 vs $-11.3625 estimate

Q4-2022: Beat consensus by 26.7% - EPS $-9 vs $-12.2715 estimate

Q1-2023: Beat consensus by 52.6% - EPS $-4.95 vs $-10.4535 estimate

Q1-2024: Missed consensus by 372.2% - EPS $-1.24 vs $-0.2626 estimate

Q4-2025: Missed consensus by 937.1% - EPS $-0.55 vs $0.0657 estimate

Q2-2025: Missed consensus by 133.0% - EPS $-0.05 vs $0.1515 estimate

Missed consensus by 5.3% - EPS $0.27 vs $0.285 estimate

Missed consensus by 19.0% - EPS $0.37 vs $0.457 estimate

Q1-2026: Missed consensus by 10.5% - EPS $0.09 vs $0.1006 estimate

Q2-2025: Beat consensus by 52.7% - EPS $0.3 vs $0.1964 estimate

Missed consensus by 17.3% - EPS $0.21 vs $0.254 estimate

Missed consensus by 12.6% - EPS $-31 vs $-27.54 estimate

Q2-2025: Beat consensus by 30.7% - EPS $-0.41 vs $-0.5916 estimate

Missed consensus by 8.9% - EPS $-30 vs $-27.54 estimate

Missed consensus by 20.3% - EPS $-24.55 vs $-20.4 estimate

Q2-2025: Beat consensus by 16.6% - EPS $0.26 vs $0.2229 estimate

Q1-2026: Missed consensus by 135.7% - EPS $-0.04 vs $0.1122 estimate

Beat consensus by 172.0% - EPS $0.34 vs $0.125 estimate

Q1-2026: Beat consensus by 14.1% - EPS $1.01 vs $0.8851 estimate

Q4-2025: Beat consensus by 13.4% - EPS $0.88 vs $0.7762 estimate

Q1-2025: Beat consensus by 31.7% - EPS $-2.76 vs $-4.0392 estimate

Q2-2025: Beat consensus by 47.2% - EPS $-1.68 vs $-3.1824 estimate

Q4-2024: Beat consensus by 32.3% - EPS $-3.48 vs $-5.1408 estimate

Q3-2025: Beat consensus by 10.8% - EPS $-2.292 vs $-2.5704 estimate

Beat consensus by 14.6% - EPS $0.59 vs $0.515 estimate

Q2-2025: Missed consensus by 5.9% - EPS $0.42 vs $0.4463 estimate

Q1-2026: Missed consensus by 23.0% - EPS $0.39 vs $0.5068 estimate

Q4-2025: Missed consensus by 12.2% - EPS $0.35 vs $0.3987 estimate

Q2-2025: Beat consensus by 27.9% - EPS $0.36 vs $0.2815 estimate

Q3-2025: Beat consensus by 17.6% - EPS $0.36 vs $0.3062 estimate

Q1-2026: Missed consensus by 132.4% - EPS $-0.03 vs $0.0927 estimate

Missed consensus by 31.9% - EPS $0.55 vs $0.808 estimate

Q4-2024: Missed consensus by 9.8% - EPS $0.79 vs $0.8754 estimate

Beat consensus by 65.8% - EPS $0.62 vs $0.374 estimate

Q1-2026: Beat consensus by 70.9% - EPS $0.34 vs $0.1989 estimate

Q2-2025: Beat consensus by 90.6% - EPS $0.44 vs $0.2308 estimate

Q4-2025: Missed consensus by 62.5% - EPS $0.17 vs $0.4539 estimate

Q3-2024: Missed consensus by 63.8% - EPS $-1.22 vs $-0.7446 estimate

Missed consensus by 82.4% - EPS $-0.93 vs $-0.51 estimate

Beat consensus by 36.3% - EPS $-0.39 vs $-0.612 estimate

Q2-2025: Beat consensus by 9.2% - EPS $1.53 vs $1.4006 estimate

Q1-2026: Beat consensus by 33.4% - EPS $2.24 vs $1.6788 estimate

Q4-2025: Beat consensus by 40.2% - EPS $1.85 vs $1.3199 estimate

Q3-2025: Beat consensus by 10.5% - EPS $1.05 vs $0.9504 estimate

Q3-2026: Missed consensus by 116.9% - EPS $-0.08 vs $0.4743 estimate

Missed consensus by 128.8% - EPS $-0.35 vs $-0.153 estimate

Q1-2026: Beat consensus by 137.7% - EPS $0.05 vs $-0.1326 estimate

Q2-2026: Missed consensus by 24.2% - EPS $0.65 vs $0.8578 estimate

Q2-2025: Missed consensus by 9.5% - EPS $-0.8 vs $-0.7307 estimate

Q4-2025: Beat consensus by 37.6% - EPS $-0.31 vs $-0.4965 estimate

Q1-2026: Missed consensus by 781.7% - EPS $-0.85 vs $-0.0964 estimate

Q3-2025: Missed consensus by 35.7% - EPS $-1.17 vs $-0.8622 estimate

Beat consensus by 360.8% - EPS $0.47 vs $0.102 estimate

Q3-2021: Missed consensus by 130.2% - EPS $-0.32 vs $1.0608 estimate

Q1-2022: Missed consensus by 131.6% - EPS $-0.6 vs $1.8972 estimate

SOL RSI 26.8 - oversold (crossed below 30)

BTC RSI 28.5 - oversold (crossed below 30)